Abstract
We report the case of a 75-year-old woman who was found to have hepatitis C virus (HCV) infection in 1987. Before treatment in 2016, she was found to have mixed cryoglobulinemia (MC). Direct-acting antiviral (DAA) treatment produced a sustained virological response 12 (SVR12). She noticed gradual muscle weakness in 2015 and the gradual development of dysarthria and dysphagia in 2017. We performed a muscle biopsy that showed inclusion body myositis (IBM). To the best of our knowledge, this is first case of a patient with HCV infection, MC, and IBM, in which MC and IBM did not improve after an SVR12 was obtained by DAA treatment.
Keywords:
direct-acting antiviral; hepatitis C virus; inclusion body myositis; mixed cryoglobulinemia; sustained virological response.
MeSH terms
-
Aged
-
Anilides / therapeutic use
-
Antiviral Agents / therapeutic use*
-
Carbamates / therapeutic use
-
Cryoglobulinemia / complications*
-
Cryoglobulinemia / diagnosis
-
Cryoglobulinemia / drug therapy
-
Cyclopropanes
-
Female
-
Hepatitis C, Chronic / complications*
-
Hepatitis C, Chronic / diagnosis
-
Hepatitis C, Chronic / drug therapy*
-
Humans
-
Lactams, Macrocyclic
-
Macrocyclic Compounds / therapeutic use
-
Myositis, Inclusion Body / complications*
-
Myositis, Inclusion Body / diagnosis
-
Myositis, Inclusion Body / drug therapy
-
Proline / analogs & derivatives
-
Ritonavir / therapeutic use
-
Sulfonamides
-
Sustained Virologic Response
-
Valine
Substances
-
Anilides
-
Antiviral Agents
-
Carbamates
-
Cyclopropanes
-
Lactams, Macrocyclic
-
Macrocyclic Compounds
-
Sulfonamides
-
ombitasvir
-
Proline
-
Valine
-
Ritonavir
-
paritaprevir